Serologicals公司将花费4500万美元得到Inte
NEW YORK (Reuters Health) - Serologicals Corp. said on Monday that it has signed an agreement to acquire privately held life science products maker The Intergen Company for roughly $45 million.
Under the terms of the transaction, Serologicals will pay Intergen $45 million in cash, minus the amount needed to complete the expansion of an Intergen manufacturing facility in Toronto. Intergen is also entitled to additional compensation, said Serologicals, based on the achievement of certain commercialization milestones.
Headquartered in Purchase, New York, Intergen sells products and technologies used in the development and manufacture of pharmaceuticals and diagnostics. Among its offerings are albumin, cell culture reagents and recombinant insulin, as well as technologies for DNA methylation, chemiluminescence and telomerase.
"Intergen's products and technologies complement our business focus and will allow us to broaden our product line to our current customers as well as afford us the opportunity to establish new customers," David Dodd, president and CEO of Serologicals, said.
Serologicals currently markets immune globulins, blood typing reagents, plasma proteins, cell culture materials and various clinical diagnostic products.
"In addition to the immediate product opportunities created by this acquisition, we are gaining access to a research and development program that should allow for the future growth of proprietary and innovative products," Dodd said.
"The Intergen R&D (research and development) staff consists of 21 individuals," Dodd noted during a Tuesday morning conference call. "Combined with our existing product development group...our company will now field an R&D team of 34."
The deal is expected to close in the fourth quarter and become accretive to Serologicals' earnings beginning next year. Last year, Intergen had revenues of $38.6 million, said Serologicals.
In late afternoon trading on the NASDAQ, shares of Atlanta-based Serologicals were up 0.55 at 16.65.
-New York Newsroom 212 273 1700, 百拇医药
Under the terms of the transaction, Serologicals will pay Intergen $45 million in cash, minus the amount needed to complete the expansion of an Intergen manufacturing facility in Toronto. Intergen is also entitled to additional compensation, said Serologicals, based on the achievement of certain commercialization milestones.
Headquartered in Purchase, New York, Intergen sells products and technologies used in the development and manufacture of pharmaceuticals and diagnostics. Among its offerings are albumin, cell culture reagents and recombinant insulin, as well as technologies for DNA methylation, chemiluminescence and telomerase.
"Intergen's products and technologies complement our business focus and will allow us to broaden our product line to our current customers as well as afford us the opportunity to establish new customers," David Dodd, president and CEO of Serologicals, said.
Serologicals currently markets immune globulins, blood typing reagents, plasma proteins, cell culture materials and various clinical diagnostic products.
"In addition to the immediate product opportunities created by this acquisition, we are gaining access to a research and development program that should allow for the future growth of proprietary and innovative products," Dodd said.
"The Intergen R&D (research and development) staff consists of 21 individuals," Dodd noted during a Tuesday morning conference call. "Combined with our existing product development group...our company will now field an R&D team of 34."
The deal is expected to close in the fourth quarter and become accretive to Serologicals' earnings beginning next year. Last year, Intergen had revenues of $38.6 million, said Serologicals.
In late afternoon trading on the NASDAQ, shares of Atlanta-based Serologicals were up 0.55 at 16.65.
-New York Newsroom 212 273 1700, 百拇医药